FDA considers making vaginal estrogen available over the counter
What happened
The U.S. Food and Drug Administration is considering making certain types of vaginal estrogen available over the counter. Dr. Dorothy Fink, former acting U.S. Secretary of Health and Human Services, commented on the policy shift, noting it could potentially save lives. The FDA stated that it requires evidence that consumers can use the product safely and effectively without physician supervision.
From moneytalksnews.com
Why it matters
The potential shift from a prescription drug to an over-the-counter product changes the distribution and accessibility of a treatment used to reduce urinary tract infections in menopausal women. This policy change is being considered nearly a year after the FDA removed its strongest warning label from estrogen products.
From moneytalksnews.com
Who's involved
- FDARegulatory agency considering the change in drug distribution
- Dorothy FinkFormer acting U.S. Secretary of Health and Human Services who commented on the policy
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- How could the push for over-the-counter estrogen availability affect the Department of Health & Human Services?HHS's regulatory scope may change as vaginal estrogen moves toward over-the-counter statusLikely
- FDA's push for OTC estrogen may change drug review standardsThe Center for Drug Evaluation and Research may adjust standards for OTC hormone approvalLikely
Keep exploring
The entities involved
- FDA
-
Dorothy Fink
American endocrinologist
Nothing else this week.